Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

Elanco Animal Health Cut to Equal-Weight From Overweight by Morgan Stanley Equity Lifestyle Raised to Overweight From Equal-Weight by Wells Fargo Five Below Cut to Underweight From Neutral by JP ...

Because this plan is a short plan based on a test of resistance it is referred to as a Short Resistance Plan. Check the time stamp on this data. Updated AI-Generated Signals for Halozyme Therapeutics ...

Fintel reports that on September 19, 2024, JP Morgan downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Halozyme Therapeutics (HALO) stock drops after J.P. Morgan downgrade, but analyst raises price target on Enhanze drug ...

Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $61.93 which represents a decrease of $-0.98 or -1.56% from the prior close of $62.91. The stock opened at $62.91 and touched ...

BOSTON, Sept. 18, 2024 /PRNewswire/ -- Below is the August 2024 Monthly Update for the Liberty All-Star Growth Fund, Inc.

Kaskela Law LLC announces that it is investigating Halozyme Therapeutics, Inc. ("Halozyme") on behalf of the company's shareholders. The investigation seeks to determine whether Halozyme and/or the ...

Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...